GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (LTS:0A8I) » Definitions » EV-to-EBIT

Genprex (LTS:0A8I) EV-to-EBIT : -0.23 (As of May. 29, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Genprex EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genprex's Enterprise Value is $4.32 Mil. Genprex's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-19.15 Mil. Therefore, Genprex's EV-to-EBIT for today is -0.23.

The historical rank and industry rank for Genprex's EV-to-EBIT or its related term are showing as below:

LTS:0A8I' s EV-to-EBIT Range Over the Past 10 Years
Min: -0.22   Med: 0   Max: 0
Current: -0.22

LTS:0A8I's EV-to-EBIT is ranked worse than
100% of 477 companies
in the Biotechnology industry
Industry Median: 8.26 vs LTS:0A8I: -0.22

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Genprex's Enterprise Value for the quarter that ended in Mar. 2025 was $2.46 Mil. Genprex's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-19.15 Mil. Genprex's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -778.49%.


Genprex EV-to-EBIT Historical Data

The historical data trend for Genprex's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genprex EV-to-EBIT Chart

Genprex Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.44 -1.17 -2.05 -0.22 -0.36

Genprex Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 -0.09 -0.02 -0.36 -0.13

Competitive Comparison of Genprex's EV-to-EBIT

For the Biotechnology subindustry, Genprex's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genprex's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genprex's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genprex's EV-to-EBIT falls into.


;
;

Genprex EV-to-EBIT Calculation

Genprex's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=4.324/-19.146
=-0.23

Genprex's current Enterprise Value is $4.32 Mil.
Genprex's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genprex  (LTS:0A8I) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Genprex's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=-19.146/2.4593916
=-778.49 %

Genprex's Enterprise Value for the quarter that ended in Mar. 2025 was $2.46 Mil.
Genprex's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genprex EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Genprex's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Genprex Business Description

Traded in Other Exchanges
Address
3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Genprex Headlines

No Headlines